In vitro induction of resistance by tissue concentrations of azithromycin, clarithromycin, cefixime and amoxicillin/clavulanate in clinical isolates of Streptococcus pyogenes

被引:3
作者
De Vecchi, E.
Nicola, L.
Zucchetti, E.
Drago, L.
机构
[1] LITA Vialba, Dept Preclin Sci, Lab Clin Microbiol, I-20157 Milan, Italy
[2] LITA Vialba, Dept Preclin Sci, Microbiol Lab, I-20157 Milan, Italy
关键词
Streptococcus pyogenes; clarithromycin; azithromycin; amoxicillin/clavulanate; cefixime; in vitro selection of resistance;
D O I
10.1179/joc.2006.18.4.379
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
This study evaluated the effects of exposure to serum, tonsils and breakpoint drug concentrations of clarithromycin, azithromycin, cefixime and amoxicillin/clavulanate on Streptococcus pyogenes susceptibility. Frequency of mutation and development of resistance after ten passages on antibiotic gradient plates, followed by ten passages without antibiotic, were determined. Phenotypes of macrolide-resistant strains grown at the end of multi-step selection were also determined. Azithromycin induced a surge of resistant strains more rapidly and frequently than clarithromycin, particularly at tonsils concentrations. With amoxicillin/clavulanate no strains showed minimum inhibitory concentrations (MICs) higher than the susceptibility breakpoint. Mutational frequencies were higher for azithromycin, at serum and breakpoint drug concentrations, than for the other drugs. Most of the macrolide resistant strains showed an MLSB, phenotype. In conclusion, the ability to prevent the occurrence of resistance in clinical isolates of S. pyogenes was similar for amoxicillin/clavulanate and clarithromycin followed by cefixime > azithromycin when tonsil drug concentrations were considered, and greater for amoxicillin/clavulanate followed by clarithromycin > cefixime > azithromycin, at breakpoint and serum concentrations.
引用
收藏
页码:379 / 388
页数:10
相关论文
共 40 条
[1]   Clarithromycin in 2003: sustained efficacy and safety in an era of rising antibiotic resistance [J].
Anzueto, A ;
Norris, S .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 (01) :1-17
[2]   Evolving resistance patterns of Streptococcus pneumoniae:: A link with long-acting macrolide consumption? [J].
Baquero, F .
JOURNAL OF CHEMOTHERAPY, 1999, 11 :35-43
[3]   Antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis and group A β-haemolytic streptococci in 2002-2003 -: Results of the multinational GRASP Surveillance Program [J].
Beekmann, SE ;
Heilmann, KP ;
Richter, SS ;
García-De-Lomas, J ;
Doern, GV .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2005, 25 (02) :148-156
[4]  
BEGUE P, 1989, PRESSE MED, V32, P1593
[5]   Effect of macrolide consumption on erythromycin resistance in Streptococcus pyogenes in Finland in 1997-2001 [J].
Bergman, M ;
Huikko, S ;
Pihlajamäki, M ;
Laippala, P ;
Palva, E ;
Huovinen, P ;
Seppälä, H .
CLINICAL INFECTIOUS DISEASES, 2004, 38 (09) :1251-1256
[6]   Practice guidelines for the diagnosis and management of group A streptococcal pharyngitis [J].
Bisno, AL ;
Gerber, MA ;
Gwaltney, JM ;
Kaplan, EL ;
Schwartz, RH .
CLINICAL INFECTIOUS DISEASES, 2002, 35 (02) :113-125
[7]   Gradient plate method to induce Streptococcus pyogenes resistance [J].
Carsenti-Etesse, H ;
Roger, PM ;
Dunais, B ;
Durgeat, S ;
Mancini, G ;
Bensoussan, M ;
Dellamonica, P .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 44 (04) :439-443
[8]   The use and resistance to antibiotics in the community [J].
Cizman, M .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 21 (04) :297-307
[9]   Selection of resistance of telithromycin against Haemophilus influenzae, Moraxella catarrhalis and streptococci in comparison with macrolides [J].
Drago, L ;
De Vecchi, E ;
Nicola, L ;
Colombo, A ;
Gismondo, MR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 54 (02) :542-545
[10]   Does this patient have strep throat? [J].
Ebell, MH ;
Smith, MA ;
Barry, HC ;
Ives, K ;
Carey, M .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 284 (22) :2912-2918